Factors associated with infarct volume growth after mechanical thrombectomy in large core infarction: ANGEL-ASPECT insights
Open Access
- 21 January 2026
- journal article
- Published by BMJ in Stroke and Vascular Neurology
Abstract
Background: Infarct volume growth (IVG) correlates with outcomes and may represent a prognostic imaging biomarker in acute ischaemic stroke due to anterior circulation large vessel occlusion (LVO). This study aims to identify factors associated with IVG after mechanical thrombectomy (MT) in patients with large core infarction. Methods: This is a post hoc analysis of the Endovascular Therapy in Anterior Circulation Large Vessel Occlusion with a Large Infarct randomised trial. IVG was calculated as final infarct volume minus baseline infarct volume (BIV). The optimal IVG threshold for predicting 90-day favourable outcomes (modified Rankin Scale score 0–3) was determined using receiver operating characteristic (ROC) curve analysis, maximising both sensitivity and specificity. Factors associated with IVG were identified using multivariate logistic regression analyses. Results: Among 228 included patients, ROC analysis identified an optimal IVG threshold of 105 mL for predicting favourable 90-day outcomes (area under the curve=0.71; specificity=0.85, sensitivity=0.53). Patients were stratified into mild (IVG <105 mL, n=150) and severe (IVG ≥105 mL, n=78) groups. Multivariate logistic regression identified BIV (OR 1.02, 95% CI 1.00 to 1.03; p<0.01), admission blood glucose (OR 1.20, 95% CI 1.04 to 1.37; p=0.01), time from puncture to recanalisation (OR 1.01, 95% CI 1.00 to 1.02; p=0.049) and recanalisation at 36 hours (±12 hours) (OR 0.19, 95% CI 0.05 to 0.72; p=0.01) as independent factors associated with IVG. Conclusion: IVG after MT significantly correlates with clinical outcomes. Identification of modifiable IVG determinants after MT may inform periprocedural management strategies in patients with large infarct due to LVO. Trial registration number: NCT04551664 .Keywords
Funding Information
- unrestricted grants from Covidien Healthcare International Trading (Shanghai), Johnson & John son MedTech, Genesis MedTech (Shanghai), and Shanghai HeartCare Medical Technology (Not applicable)
- Noncommunicable Chronic Diseases-National Science and Technology Major Project (2023ZD0505400)
This publication has 35 references indexed in Scilit:
- Thrombectomy for Stroke With Large Infarct on Noncontrast CTJAMA, 2024
- Endovascular thrombectomy for acute ischaemic stroke with established large infarct: multicentre, open-label, randomised trialThe Lancet, 2023
- Trial of Endovascular Therapy for Acute Ischemic Stroke with Large InfarctNew England Journal of Medicine, 2023
- Trial of Endovascular Thrombectomy for Large Ischemic StrokesNew England Journal of Medicine, 2023
- Brush sign and collateral supply as potential markers of large infarct growth after successful thrombectomyEuropean Radiology, 2023
- Endovascular Therapy for Acute Stroke with a Large Ischemic RegionNew England Journal of Medicine, 2022
- The Effect of Hyperglycemia on Infarct Growth after Reperfusion: An Analysis of the DEFUSE 3 trialJournal of Stroke and Cerebrovascular Diseases, 2021
- Outcomes of Endovascular Thrombectomy vs Medical Management Alone in Patients With Large Ischemic CoresJAMA Neurology, 2019
- Mediation of the Relationship Between Endovascular Therapy and Functional Outcome by Follow-up Infarct Volume in Patients With Acute Ischemic StrokeJAMA Neurology, 2019
- Hyperglycemia in acute ischemic stroke: pathophysiology and clinical managementNature Reviews Neurology, 2010